Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00632632 · ClinicalTrials.gov registry record · NA

Virtual Reality & D-cycloserine (DCS) for Posttraumatic Stress Disorder (PTSD)

A NA study, sponsored by Weill Medical College of Cornell University.

Completed
Registry status
NA
Development phase
25
Enrollment target

NCT00632632 is a NA study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 25 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00632632, a NA study, has completed, sponsored by Weill Medical College of Cornell University.

COMPLETED
Registry status
NA
Development phase
25 participants
Enrollment target

Study Summary

This study proposes to evaluate the effects of D-cycloserine (DCS) combined with Virtual Reality exposure therapy in a sample of patients who developed posttraumatic stress disorder (PTSD) following either the events of September 11, 2001, or military service in the war in Iraq. In addition, this study hopes to determine whether a common human genetic single nucleotide polymorphism (SNP) in a growth factor, brain derived neurotrophic factor, BDNF (Val66Met), predicts treatment response to PTSD. Overall, this study aims 1) to determine if subjects administered DCS show a significantly larger decrease in symptoms of PTSD as compared to those administered a placebo, 2) to determine if subjects administered DCS show a decrease in PTSD symptomatology significantly earlier (as measured by weeks) than those administered a placebo, 3) to determine if differences in symptomatology are evident at a 6-month follow-up and indicate long-term differences between groups, and 4) to determine if the BDNF SNP predicts treatment response.

Interventions

  • OTHER Placebo
  • DRUG D-Cycloserine

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2005-01
Est. Completion 2012-12
Phase NA

What the Registry Record Tells You About NCT00632632

The ClinicalTrials.gov registry entry for NCT00632632 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00632632 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00632632 about?

NCT00632632 is a clinical study titled "Virtual Reality & D-cycloserine (DCS) for Posttraumatic Stress Disorder (PTSD)". This study proposes to evaluate the effects of D-cycloserine (DCS) combined with Virtual Reality exposure therapy in a sample of patients who developed posttraumatic stress disorder (PTSD) following either the events of September 11, 2001, or military service in the war in Iraq. In addition, this st...

What is the current status of trial NCT00632632?

This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2005-01. Estimated completion is 2012-12.

What interventions are being tested in trial NCT00632632?

The interventions under investigation include: Placebo (OTHER), D-Cycloserine (DRUG).

Who is sponsoring clinical trial NCT00632632?

This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.